Improving immunotherapy for glioblastoma treatment
Advancing treatment and understanding of immunotherapy in glioblastoma
This study is looking for ways to improve treatments for glioblastoma, a tough brain tumor, by testing new methods to help the immune system fight the cancer, and patients with recurring glioblastoma can join early trials to try out these innovative therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10910087 on NIH RePORTER |
What this research studies
This research focuses on enhancing immunotherapy approaches for glioblastoma, a challenging brain tumor. The project involves collaboration between two leading cancer centers to explore how to effectively deliver immunotherapy across the blood-brain barrier and develop new treatment strategies. Patients with recurrent glioblastoma may participate in early clinical trials that test innovative therapies, including the use of immune checkpoint inhibitors combined with doxorubicin and ultrasound techniques to improve drug delivery. The research aims to provide a deeper understanding of glioblastoma and its treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with recurrent glioblastoma.
Not a fit: Patients with glioblastoma who are not recurrent or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using immunotherapy for glioblastoma, but this approach aims to address specific challenges that have not been fully explored.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Butowski, Nicholas a — University of California, San Francisco
- Study coordinator: Butowski, Nicholas a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.